Covered recipient · General Payments record
NAKEISHA ANNE OTTO-STEWART
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,623.38
- Reported across 75 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $274.73 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $55.20 | 3 |
| DEXCOM, INC. | $53.36 | 3 |
| ABBVIE INC. | $40.24 | 2 |
| Astellas Pharma US Inc | $36.48 | 2 |
| Lilly USA, LLC | $33.25 | 2 |
| Corcept Therapeutics | $18.99 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.79 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.42 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.97 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105162775 | CMS |
| ABBVIE INC. | $20.27 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105162777 | CMS |
| Astellas Pharma US Inc | $23.24 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139363397 | CMS |
| Astellas Pharma US Inc | $13.24 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139270830 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $18.79 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086234395 | CMS |
| Corcept Therapeutics | $18.99 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117731204 | CMS |
| Dexcom, Inc. | $17.20 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324603 | CMS |
| Dexcom, Inc. | $17.20 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324605 | CMS |
| Dexcom, Inc. | $18.96 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324607 | CMS |
| Lilly USA, LLC | $15.09 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135260195 | CMS |
| Lilly USA, LLC | $18.16 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135175415 | CMS |
| Novo Nordisk Inc | $17.82 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096863371 | CMS |
| Novo Nordisk Inc | $17.13 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097133229 | CMS |
| Novo Nordisk Inc | $20.25 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097570419 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.42 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153532982 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.